Amanda M Brandow

List of Publications by Year
in descending order

53	1,814	279798	289244
papers	citations	23 h-index	40 g-index

53	53	53	1659
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion and Apheresis Science, 2022, 61, 103304.	1.0	2
2	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€"Acute Pain Episodes in Sickle Cell Disease. Annals of Internal Medicine, 2022, 175, HO2-HO3.	3.9	0
3	Recommendation to reality: Closing the transcranial Doppler screening gap for children with sickle cell anemia. Pediatric Blood and Cancer, 2021, 68, e28831.	1.5	5
4	COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Advances, 2021, 5, 1915-1921.	5.2	54
5	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Advances, 2021, 5, 2839-2851.	5.2	14
6	Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Advances, 2021, 5, 2717-2724.	5.2	47
7	Vitamin D Levels: Associations with Acute Pain Events and Self-Reported Pain in Children with Sickle Cell Disease. Blood, 2021, 138, 3089-3089.	1.4	0
8	Opioid-Related Mortality for Individuals with Sickle Cell Disease Remains Low with No Significant Increase during 2013-2019. Blood, 2021, 138, 124-124.	1.4	0
9	Neuropathic pain in individuals with sickle cell disease. Neuroscience Letters, 2020, 714, 134445.	2.1	20
10	Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20â€"May 21, 2020. Emerging Infectious Diseases, 2020, 26, 2473-2476.	4.3	97
11	Neuropathic pain is associated with poor healthâ€related quality of life in adolescents with sickle cell disease: A preliminary report. Pediatric Blood and Cancer, 2020, 67, e28698.	1.5	10
12	Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis and Cannabinoid Research, 2020, 5, 255-262.	2.9	14
13	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Advances, 2020, 4, 2656-2701.	5.2	184
14	Phase 2 trial of montelukast for prevention of pain in sickle cell disease. Blood Advances, 2020, 4, 1159-1165.	5.2	7
15	Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection. Blood, 2020, 136, 7-8.	1.4	2
16	Neuropathic pain in sickle cell disease: measurement and management. Hematology American Society of Hematology Education Program, 2020, 2020, 553-561.	2.5	1
17	Plasma-Based Inflammatory Signatures in Patients with Sickle Cell Disease during Baseline Health and Acute Pain. Blood, 2020, 136, 25-26.	1.4	18
18	Gabapentin alleviates chronic spontaneous pain and acute hypoxiaâ€related pain in a mouse model of sickle cell disease. British Journal of Haematology, 2019, 187, 246-260.	2.5	12

#	Article	IF	Citations
19	Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain. PLoS ONE, 2019, 14, e0216994.	2.5	20
20	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Advances, 2019, 3, 3945-3950.	5.2	14
21	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances, 2019, 3, 3982-4001.	5.2	51
22	Interventions for treating neuropathic pain in people with sickle cell disease. The Cochrane Library, 2019, 7, CD012943.	2.8	6
23	Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events. Pain, 2019, 160, 407-416.	4.2	27
24	Neuropathic Pain Is Associated with Poor Health-Related Quality of Life in Adolescents with Sickle Cell Disease. Blood, 2019, 134, 417-417.	1.4	0
25	Key Components of Pain Management for Children and Adults with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2018, 32, 535-550.	2.2	35
26	Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis. Pediatric Blood and Cancer, 2018, 65, e27420.	1.5	15
27	Red blood cell transfusion therapy for sickle cell patients with frequent painful events. Pediatric Blood and Cancer, 2018, 65, e27423.	1.5	13
28	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	1.5	57
29	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	1.4	3
30	Patientâ€reported neuropathic pain in adolescent and young adult cancer patients. Pediatric Blood and Cancer, 2017, 64, e26364.	1.5	5
31	Sickle cell disease: a natural model of acute and chronic pain. Pain, 2017, 158, S79-S84.	4.2	41
32	Pain-measurement tools in sickle cell disease: where are we now?. Hematology American Society of Hematology Education Program, 2017, 2017, 534-541.	2.5	17
33	Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. American Journal of Hematology, 2016, 91, 1175-1180.	4.1	23
34	Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use. British Journal of Haematology, 2016, 175, 237-245.	2.5	30
35	Clinical Interpretation of Quantitative Sensory Testing as a Measure of Pain Sensitivity in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2016, 38, 288-293.	0.6	31
36	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306.	2.0	14

#	Article	IF	Citations
37	Patient-reported prevalence of neuropathic pain in adolescent and young adult oncology patients.. Journal of Clinical Oncology, 2016, 34, 10577-10577.	1.6	1
38	Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature. Pediatric Blood and Cancer, 2015, 62, 1501-1511.	1.5	51
39	The Use of Neuropathic Pain Drugs in Children With Sickle Cell Disease Is Associated With Older Age, Female Sex, and Longer Length of Hospital Stay. Journal of Pediatric Hematology/Oncology, 2015, 37, 10-15.	0.6	26
40	Do difficulties in swallowing medication impede the use of hydroxyurea in children?. Pediatric Blood and Cancer, 2014, 61, 1536-1539.	1.5	17
41	Neuropathic pain in patients with sickle cell disease. Pediatric Blood and Cancer, 2014, 61, 512-517.	1.5	84
42	Update on the use of hydroxyurea therapy in sickle cell disease. Blood, 2014, 124, 3850-3857.	1.4	82
43	Children with Sickle Cell Disease on Chronic Red Cell Transfusion Experience Fewer Hospitalizations for Acute Vaso-Occlusive Episodes Irrespective of the Indication for Transfusion. Blood, 2014, 124, 4282-4282.	1.4	0
44	Patients with sickle cell disease have increased sensitivity to cold and heat. American Journal of Hematology, 2013, 88, 37-43.	4.1	127
45	Academic Attainment Findings in Children With Sickle Cell Disease. Journal of School Health, 2013, 83, 548-553.	1.6	33
46	Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood, 2011, 118, 3376-3383.	1.4	133
47	The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations. Pediatric Blood and Cancer, 2011, 56, 789-793.	1.5	30
48	Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. American Journal of Hematology, 2011, 86, 804-806.	4.1	25
49	Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. American Journal of Hematology, 2010, 85, 611-613.	4.1	93
50	Vasoâ€occlusive painful events in sickle cell disease: Impact on child wellâ€being. Pediatric Blood and Cancer, 2010, 54, 92-97.	1.5	79
51	Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Review of Hematology, 2010, 3, 255-260.	2.2	80
52	Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. British Journal of Haematology, 2009, 144, 782-788.	2.5	59
53	Interventions for treating neuropathic pain in people with sickle cell disease. The Cochrane Library, 0, , .	2.8	5